New Insights in Psychiatric Disorder Psychopharmacology
Author Contributions
Funding
Conflicts of Interest
List of Contributions
- Dao, J.; Saran, S.; Wang, M.; Michael, C.; Phan N-y Bellon, A. A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia. Brain Sci. 2023, 13, 368. https://doi.org/10.3390/brainsci13020368.
- Messina, A.; Concerto, C.; Rodolico, A.; Petralia, A.; Caraci, F.; Signorelli, M.S. Is It Time for a Paradigm Shift in the Treatment of Schizophrenia? The Use of Inflammation-Reducing and Neuroprotective Drugs—A Review. Brain Sci. 2023, 13, 957. https://doi.org/10.3390/brainsci13060957.
- Tsapakis, E.M.; Diakaki, K.; Miliaras, A.; Fountoulakis, K.N. Novel Compounds in the Treatment of Schizophrenia—A Selective Review. Brain Sci. 2023, 13, 1193. https://doi.org/10.3390/brainsci13081193.
- de Filippis, R.; Staltari, F.A.; Aloi, M.; Carbone, E.A.; Rania, M.; Destefano, L.; Steardo, L., Jr.; Segura-Garcia, C.; De Fazio, P. Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study. Brain Sci. 2023, 13, 577. https://doi.org/10.3390/brainsci13040577.
- Dogaru, I.-A.; Puiu, M.G.; Manea, M.; Dionisie, V. Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression. Brain Sci. 2022, 12, 1403. https://doi.org/10.3390/brainsci12101403.
- Alvarez-Mon, M.A.; García-Montero, C.; Fraile-Martinez, O.; Quintero, J.; Fernandez-Rojo, S.; Mora, F.; Gutiérrez-Rojas, L.; Molina-Ruiz, R.M.; Lahera, G.; Álvarez-Mon, M.; et al. Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. Brain Sci. 2023, 13, 333. https://doi.org/10.3390/brainsci13020333.
- Lalegani, E.; Eissazade, N.; Shalbafan, M.; Salehian, R.; Shariat, S.V.; Askari, S.; Orsolini, L.; Soraya, S. Safety and Efficacy of Drug Holidays for Women with Sexual Dysfunction Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) Other than Fluoxetine: An Open-Label Randomized Clinical Trial. Brain Sci. 2023, 13, 1397. https://doi.org/10.3390/brainsci13101397.
- Nohesara, S.; Mostafavi Abdolmaleky, H.; Thiagalingam, S. Substance-Induced Psychiatric Disorders, Epigenetic and Microbiome Alterations, and Potential for Therapeutic Interventions. Brain Sci. 2024, 14, 769. https://doi.org/10.3390/brainsci14080769.
- Ragnhildstveit, A.; Slayton, M.; Jackson, L.K.; Brendle, M.; Ahuja, S.; Holle, W.; Moore, C.; Sollars, K.; Seli, P.; Robison, R. Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions. Brain Sci. 2022, 12, 382. https://doi.org/10.3390/brainsci12030382.
References
- Mao, Z.; Dong, F.; Li, A.; Li, F.; Zhu, J.; Du, X.; Wu, G.; Deng, H.; Yu, X.; Liu, J.; et al. Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients. BMC Psychiatry 2024, 24, 959. [Google Scholar] [CrossRef] [PubMed]
- Zandifar, A.; Panahi, M.; Badrfam, R.; Qorbani, M. Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: A randomized double-blind, placebo-controlled clinical trial. BMC Psychiatry 2024, 24, 163. [Google Scholar] [CrossRef] [PubMed]
- Moshfeghinia, R.; Sanaei, E.; Mostafavi, S.; Assadian, K.; Sanaei, A.; Ayano, G. The effects of L-theanine supplementation on the outcomes of patients with mental disorders: A systematic review. BMC Psychiatry 2024, 24, 886. [Google Scholar] [CrossRef]
- Kwaśny, A.; Wilkowska, A.; Cubała, W.J. Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: A systematic review of clinical trials. Front. Psychiatry 2024, 15, 1477996. [Google Scholar] [CrossRef] [PubMed]
- Pattanaseri, K.; Lortrakul, J.; Jaisin, K.; Srifuengfung, M.; Sa-nguanpanich, N.; Viravan, N.; Pariwatcharakul, P.; Makarasara, W.; Ratta-apha, W. A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression. BMC Psychiatry 2024, 24, 512. [Google Scholar] [CrossRef] [PubMed]
- Gao, W.; Gao, Y.; Xu, Y.; Liang, J.; Sun, Y.; Zhang, Y.; Shan, F.; Ge, J.; Xia, Q. Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder. BMC Psychiatry 2024, 24, 449. [Google Scholar] [CrossRef] [PubMed]
- Khazaie, H.; Sadeghi, M.; Khazaie, S.; Hirshkowitz, M.; Sharafkhaneh, A. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Front. Psychiatry 2022, 13, 1070522. [Google Scholar] [CrossRef] [PubMed]
- Shalbafan, M.; Malekpour, F.; Tadayon Najafabadi, B.; Ghamari, K.; Dastgheib, S.-A.; Mowla, A.; Shirazi, E.; Eftekhar Ardebili, M.; Ghazizadeh-Hashemi, M.; Akhondzadeh, S. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. J. Psychopharmacol. 2019, 33, 1407–1414. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shalbafan, M.; Orsolini, L. New Insights in Psychiatric Disorder Psychopharmacology. Brain Sci. 2025, 15, 319. https://doi.org/10.3390/brainsci15030319
Shalbafan M, Orsolini L. New Insights in Psychiatric Disorder Psychopharmacology. Brain Sciences. 2025; 15(3):319. https://doi.org/10.3390/brainsci15030319
Chicago/Turabian StyleShalbafan, Mohammadreza, and Laura Orsolini. 2025. "New Insights in Psychiatric Disorder Psychopharmacology" Brain Sciences 15, no. 3: 319. https://doi.org/10.3390/brainsci15030319
APA StyleShalbafan, M., & Orsolini, L. (2025). New Insights in Psychiatric Disorder Psychopharmacology. Brain Sciences, 15(3), 319. https://doi.org/10.3390/brainsci15030319